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PERICARDIAL DISEASE 
Immunosuppressive Therapy Prevents Recurrent Pericarditis 
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Objectives. This study reviews the clinical outcome of a series of 
patients with recurrent pericarditis before and after immunosup- 
pressive therapy. 
Background. Despite anti-inflammatory treatment, some pa- 
tients with acute pericarditis experience repeated relapses of the 
disease. The use of steroids for the treatment of recurrent 
pericarditis remains controversial. 
Methods. Twelve patients (4 women, 8 men; mean [-SD] age 
35.9 -+ 17.2 years, range 15 to 65) with recurrent pericarditis 
unrelated to any systemic disease were selected. All 12 patients 
previously received ineffective short.term courses of low dose 
steroids and had a total of 39 relapses during a mean follow-up 
period of 14.2 months (range 4 to 50). A 3-month course of 
treatment with prednisone, at an immunosuppressive dosage, was 
started (1 to 1.5 mg/kg body weight per day for 4 weeks, then 
gradually withdrawn). When prednisone reduction was undertaken, 
all patients started a 5-month course of treatment with aspirin 
(1.6 g/day until steroid suspension, then reduced to 0.8 g/day). 
Results. During a mean follow-up period of 41.6 months (range 
7 to I04), immunosuppressive treatment with high dose pred- 
nisone resulted in stable remission in all except one patient, who 
experienced one relapse. In this patient, the addition of azathio- 
prine to prednisone induced a persistent remission, which re- 
mained after 1.year follow-up. During treatment, three patients 
had severe steroid-related adverse effects that in two patients 
required replacement of prednisone with azathioprine and cyclo- 
phosphamide, respectively. This variation in the immunosuppres- 
sire regimen did not modify the favorable clinical outcome. 
Conclusions. The dose and duration of steroid treatment are 
critical factors in preventing recurrent pericarditis. High dose 
prednisone with aspirin should be considered in the treatment of 
recurrent pericarditis resistant to anti-inflammatory therapy. 
Cyclophosphamide or azathioprine should be reserved for pa- 
tients who do not respond to high dose prednisone or who 
experience severe complications related to steroid therapy. 
(J Am CoU Cardio11995;26:1276-9) 
Primary acute pericarditis is commonly a self-limiting disease 
with a good prognosis (1). Nevertheless, repeated episodes of 
pericardial inflammation may occur in a subset of patients over 
a period of months or years (2). The characteristic pattern of 
recurrent pericarditis is the frequent appearance of disabling 
chest pain with or without pericardial effusion. Rare compli- 
cations have been reported (3), including pericardial tampon- 
ade, hemopericardium and myocarditis. 
Although the etiology of idiopathic recurrent pericarditis 
remains unknown, an immunologic pathogenesis is presumed 
(2-4). Despite this assumption, the utilization of immunosup- 
pressive drugs in this disease remains controversial (3,5) 
because of the limited number of clinical studies (6-8). There 
is general agreement regarding the use of nonsteroidal nti- 
inflammatory drugs (NSAIDs) as initial therapy, whereas 
steroid treatment is usually reserved for selected resistant 
cases. However, some investigators (7,8) consider long-term 
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treatment with steroids contraindicated in recurrent pericardi- 
tis because of a reported tendency to favor the persistence and 
recurrence ofpericardial inflammation i  uncontrolled studies. 
To evaluate the effect of immunosuppressive therapy in 
recurrent pericarditis, we retrospectively reviewed our experi- 
ence in a series of 12 consecutive patients who had repeated 
relapses of acute pericarditis in the absence of any systemic 
disease usually associated with pericardial inflammation. All 
patients had a history of previous ineffective treatment with 
NSAIDs and low dose steroids. Treatment with high doses of 
prednisone or other immunosuppressive agents (cyclophos- 
phamide or azathioprine) steadily suppressed further elapses 
of the disease. Our findings uggest the critical role of immu- 
nosuppressive therapy in preventing the recurrence of pericar- 
dial inflammation. On the basis of these data, a treatment 
schedule for recurrent pericarditis is proposed. 
Methods  
Study group. Seventeen patients (10 male, 7 female) with a 
history of recurrent acute pericarditis, admitted to our depart- 
ment from September 1985 to May 1994, were reviewed. The 
criteria for study inclusion were persistence or recurrence of 
long-lasting chest pain ->3 months after the original attack, 
associated with fever or pericardial friction rub, specific elec- 
trocardiographic changes or echocardiographic findings of 
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Table 1. Characteristics, Steroid Treatment Modati~' and Clinical Outcome of 12 Patients With 
Recurrent Pericarditis Before Immunosuppressive Therapy 
Steroid Treatment 
Age at 
Pt No./ Onset Highest Dose Duration No. of Follow-Up 
Gender (yr) Etiology (mg/kg per day) (days) Relapses (too) 
1/M 62 PMI 0.1 45 2 8 
2/M 15 ID 0.07 30 2 6 
3/M 26 PO 0.2 2l 3 12 
4/M 27 ID 0.2 30 4 9 
5/F 21 ID 0.9 7 3 7 
6/M 35 ID 0.3 3(1 3 6 
7/M 38 ID 0.6 Tapered over 45 2 4 
8/M :.4 PMI 0.6 Tapered over 30 5 36 
9/M 23 1D 0.6 Tapered over 30 4 20 
lt)/F 56 ID !1.3 45 6 50 
11/F 05 It) II.fi Tapered over 30 2 5 
12/F 19 ID (I.2 45 3 8 
F female: ID - idiopathic: M male: PMI postmyoeardial inf rction; PO = postoperative (cardiothoracic 
surgery,): Pt = patient. 
pericardial effusion. Five patients were excluded because of the 
presence of an associated systemic disease (three patients with 
systemic lupus erythematosus, one with primary immunodefi- 
ciency and one with rheumatoid arthritis). Of the 12 patients (8 
men, and 4 women; mean [_+SD] age 35.9 _+ 17.2 years, range 
15 to 65) included in the present study, 9 had idiopathic 
recurrent pericarditis, 2 had recurrent pericarditis secondary, to 
myocardial infarction, and 1 had postoperative r current peri- 
carditis. 
Patients' records were retrospectively reviewed, and the 
relation between pericarditis relapses and modalities of treat- 
ment followed before and after referral to our department 
were carefully checked, with particular attention to the dose 
and duration of steroid therapy. Adverse effects were also 
investigated. 
Therapeut ic  regimens. At the time of first evaluation, all 12 
patients had a history of previous ineffective anti-inflammatory 
treatment. As shown in Table 1, all patients received steroid 
treatment (prednisone or deflazacort), the highest dose rang- 
ing from 0.07 to 0.9 mg/kg body weight per day (mean 0.3 ± 
0.2). Total duration of corticosteroid treatment varied from 7 
to 45 days (mean 32.3 _+ 11.4). Before steroid treatment, 11 
patients underwent ineffective therapy with NSAIDs. 
Therapeutic schedules followed by each patient after being 
referred to our department are reported in Table 2. Oral 
administration of prednisone was started in all patients at an 
initial dose ranging from 1 to 1.5 mg/kg per day (mean 1.1 _+ 
0.2). The higher dose was rese~ed for patients with cardiac 
tamponade or more severe symptoms. The initial dose was 
maintained for at least 4 weeks and then gradually reduced 
until discontinuation within 3 months (mean 85 _+ 69 days). 
When prednisone reduction was undertaken. 1.6 &/day of 
aspirin was given until prednisone discontinuation (2 months). 
The aspirin daily dose was then reduced to 0.8 g/day and 
maintained for a further 3 months. 
Statist ical  analysis .  The effect of immunosuppressive th r- 
apy versus the previous ineffective anti-inflammatoD~ treat- 
ment to prevent recurrence of pericarditis was compared by 
the Cox proportional hazards model (9,10) in which the 
treatment schedule was the only independent variable and the 
time free of recurrence was the follow-up time. Each patient 
was reintroduced into the analysis after every episode of 
pericarditis. Results are expressed as mean value + SD. 
Resu l ts  
Follow-up data. The number of relapses recorded in our 
patients before and after referral to our department are shown 
in Tables 1 and 2, respectively. After all patients were consid- 
ered as a group after previous short-term low dose steroid 
treatment, there were 39 relapses (from two to six in each 
patient) during a follow-up period of 4 to 50 months (mean 
Table 2. Immunosuppressive Tr atment Modality and Clinical 
Outcome in 12 Patients With Recurrent Pericarditis 
Pt No. 
Prednisone 
Dose Other No. of Follow-Up 
(mgq~g per day') Drugs Relapses (mo) 
I 1 * Ctx 0 104 
2 1.55 No 0 96 
3 1 No 0 58 
4 1.5 No 0 40 
5 1 No 0 39 
6 1 No 0 37 
7 1 No 0 32 
8 I No 0 30 
t) 1 No 0 25 
I0 1.5 No 1 3 
1.5 AZ{ 0 21 
11 I No 0 8 
12 I§ AZ 0 7 
~Withdrawn after first week of treatment due to hyperglycemia, tWithdrawn 
at tburth week for severe cushingoid syndrome. :[:In combination with pred- 
nisone. §Withdrawn after first week of treatment for severe psychiatric symp- 
l(nn~. AZ = azathioprine; Ctx cyclophosphamide; Pt = patient. 
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Figure I. Effect of high dose immunosuppressive therapy (dashed 
curve) versus previous low dose ineffective anti-inflammatory treat- 
ment (solid curve) to prevent recurrence ofpericarditis. Cox propor- 
tional hazards model (beta -3.67, SE 1.03, p < 0,0001). 
14.2 _+ 14.3). By contrast, after long-term immunosuppressive 
treatment with high dose prednisone and cyclophosphamide or 
azathioprine, only one relapse occurred during a period of 
observation that ranged from 7 to 104 months (mean 41.6 + 
30.5). The relapse occurred in Patient 7, who did not receive 
aspirin because of a history of chronic peptic ulcer, when the 
daily dose of prednisone was tapered to <0.06 mg/kg per day. 
The addition of azathioprine (150 rag/day orally for 3 months, 
then reduced to 100 rag/day and maintained for a further 9 
months) steadily suppressed the clinical symptoms of pericar- 
ditis. 
Figure 1 shows the cumulative proportion of recurrence of 
pericarditis as estimated by the Cox model. We computed a
relative risk of 0.025 of recurrence of pericarditis in immuno- 
suppressive therapy versus anti-inflammatory treatment peri- 
ods as exp (beta) by the Cox proportional hazards model (beta 
-3.67, SE 1.03, p < 0.0001). 
Adverse effects of immunosuppression. Complications re- 
lated to high dose prednisone were observed in three patients: 
Patient 12 developed severe psychiatric symptoms (agitation 
and confusion) after 1 week of treatment; Patient 1 had 
hyperglycemia after few days of therapy; Patient 2 had severe 
cushingoid syndrome that appeared after 4 weeks of treatment. 
In all three patients, steroid treatment was rapidly with- 
drawn, leading to the disappearance of adverse effects. To 
maintain immunosuppression, Patient 12 received azathio- 
prine (150 rag/day orally for 2 months, thereafter reduced to 
100 mg/day and maintained for a further 5 months). Patient 1 
was given cyclophosphamide (150 mg/day orally for 2 months, 
thereafter reduced to 100 mg/day and maintained for a further 
3 months). After completing immunosuppressive tr atment 
with azathioprine or cyclophosphamide, both patients regu- 
larly received aspirin therapy, as scheduled. Because Patient 2 
had already accomplished 4 weeks of immunosuppressive 
treatment with high dose prednisone, only aspirin therapy was 
added (2.4 g/day for 1 month, thereafter reduced to 1.6 g/day 
for a further 4 months and finally tapered until suspension 
within 1 month). 
During treatment, all patients underwent gastric protection. 
Mild gastric discomfort, which did not modify the therapeutic 
regimen, was observed in four patients during concomitant 
administration of prednisone and aspirin. 
Discuss ion  
Our study shows that immunosuppressive tr atment is 
effective in preventing relapses of pericardial inflammation i  
patients with recurrent pericarditis. 
Efficacy of steroids in recurrent pericarditis. The role of 
steroids in the treatment of acute pericarditis is not well 
defined (2,3). In particular, there is concern about maintaining 
steroid therapy in patients with repeated relapses, inasmuch as 
some investigators have reported (7,8) that these drugs may 
perpetuate pericardial inflammation instead of resolving it. 
However, the therapeutic action of steroids is dose dependent. 
An anti-inflammatory effect is usually obtained with the ad- 
ministration of 0.1 to 0.3 mg/kg per day of prednisone; 
however, to produce faster immunosuppressive action, higher 
doses are required (range 1 to 2 mg/kg per day) (11). Thus, low 
dose or short-term steroid treatment may be inadequate to 
inhibit immunologic mechanisms from taking place during a 
relapse of pericarditis. However, the resolution of pericardial 
inflammation experienced by our patients after a full thera- 
peutic cycle of high dose prednisone could be related to the 
induction of lasting immunosuppression. Our hypothesis  also 
supported by the recently reported (12) efficacy of methylpred- 
nisolone given as pulse therapy in patients with recurrent 
pericarditis and by the finding that in three of our patients 
other immunosuppressive agents (cyclophosphamide or aza- 
thioprine), alone or in combination with high dose prednisone, 
resulted in stable remission without evidence of toxicity. 
Continuous, long-term aspirin administration for 5 months 
in 11 of our 12 patients represents the second therapeutic 
choice that may account for the favorable clinical outcome 
reported. The rationale was to ensure adequate anti- 
inflammatory protection during the critical phase of pred- 
nisone reduction and after its discontinuation. The only patient 
who did not receive aspirin because of peptic ulcer (Patient 10) 
had a relapse of pericarditis when prednisone was reduced to 
<0.06 mg/kg per day. On the basis of this single case we cannot 
conclude that the addition of aspirin to prednisone is more 
effective than steroid monotherapy in preventing pericarditis 
relapse. Thus, further clinical studies are needed to verify the 
effectiveness and safety of this association i  a larger series of 
patients. 
Other immunosuppressive r gimes. It has been reported 
(13-15) that alternative treatments for recurrent pericarditis, 
including interferon and surgical intervention, are not always 
effective. We suggest hat in patients with acute pericarditis, 
NSAIDs monotherapy should be considered first and that low 
doses of steroids hould be avoided because of the possible risk 
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of perpetuating instead of resolving pericardial inflammation. 
High dose prednisone for at least 4 weeks, gradually withdrawn 
over a 3-month period, should be reserved for NSAIDs- 
resistant patients or those who experience a relapse despite 
steroid therapy at anti-inflammatory doses. Although further 
studies are needed, the addition of aspirin seems to enhance 
the effectiveness of prednisone therapy during the critical 
phase of prednisone reduction. Immunosuppressive treatment 
with cyclophosphamide, azathioprine or, as recently reported, 
colchicine (2,16-19) should be reserved for patients with 
recurrent pericarditis resistant to high dose prednisone or for 
those who are intolerant to steroid therapy. The therapeutic 
potential of other recent immunosuppressive drugs in recur- 
rent pericarditis, including cyclosporin A, FK-506 and rapamy- 
cin, remains to be established. 
Conclusions. Before attempting alternative therapeutic 
treatments in patients with recurrent pericarditis, clinicians 
should critically evaluate the dose and duration of previous 
steroid therapy, keeping in mind the possibility of long-term 
immunosuppressive treatment with high dose prednisone and 
other immunosuppressive agents. 
We thank Denise Kilmartin for help in the manuscript preparation. 
References  
1. Shabetai R. Acute pericarditis. Cardiol Clin 1990:4:639-44. 
2. Douchet M, Attali P, Finkler JL. A case of recurrent pericarditis treated by 
colchicine. Eur Heart J 1993:14:431-2. 
3. Fowler NO. Recurrent pericarditis. Cardiol Clin 1990;4:621-6. 
4. Robinson J, Bridgen W. Recurrent acute pericarditis. BMJ 1968;2:272-5. 
5. Asplen CH, Levine HD. Azathioprine therapy of steroid responsive pericar- 
ditis. Am Heart J 1970;80:109-11. 
6. Fowler NO, Harbin Ill AD. Recurrent acute pericarditis: follow-up study of 
31 patients. J Am Coil Cardiol 1986;7:300-5. 
7. Fromcnt R, Perrin A, Saint-Pierre A, et al. Efflorescence de p6ricardites 
idiopathiques r6cidivantes. R61e probable des antibiotiques et de la cortico- 
th6rapie. J Med Lyon 1970;25:113-23. 
8. Godcau P, Derrida JP, Bletry G, et al. P6ricardites aigu~s r6cidivantes et 
cortico-d6pendance: apropos de 10 observations. Semin Hop Paris 1975;51: 
2393-400. 
t~. Cox DR. Regression models and life time. J R Stat Soc 1994;34:187-220. 
10. Dixon WJ. BMDP Statistical Software. Los Angeles: University Press of 
California. 1992. 
11. Winkelstein A. lmmunosuppressive th rapy. In: Stites DP, Terr AI, Parslow 
TG. editors. Basic and Clinical Immunology. E. Norwalk (CT): Appleton & 
I_ange, 1994:765-80. 
12. Melchior TM, Ringsdal V, Hildebrand P, Torp-Pedersen C. Recurrent acute 
idiopathic pericarditis treated with intravenous methylprednisone given as 
pulse therapy. Am Heart J 1992;123:1086-8. 
13. Hatcher CR, Lngue RB, Logan WB Jr, Symbas RB, Mansour DA, Abbot 
OA. Pericardiectomy for recurrent pericarditis. J Thorac Cardiovasc Surg 
1971;62:371-8. 
14. Goldfarb B, Gold D, Latts E, et al. Recurrent "pericardial pain" after 
pericardieetomy forrecurrent acute benign pericarditis. Circulation 1966;33: 
283-6. 
15. Yoneda 8, Ohte N, Samoto T, et al. Two cases of viral myocarditis and one 
case of viral pericarditis. Jpn Circ 1982;46:1222-6. 
16. Guindo J, Rodriguez De La Serna A, et al. Recurrent pericarditis. Relief 
with colchicine. Circulation 1990;82:1117-9. 
17. Rodriguez De La Serna A, Guindo J, Marti Claramunt V, Bayes De Luna A. 
Colchicine for recurrent pericarditis. Lancet 1987;2:1517. 
IX. 8podick DH. Colchicine therapy of recurrent pericarditis. Circulation 1991; 
83:1830-1. 
It). Adler Y. Zandman-Goddard G, Ravid M. Usefulness of eolchicine in 
preventing recurrences of pericarditis. Am J Cardiol 1994;73:916-7. 
